Prescribing pattern of proton pump inhibitors among patients admitted to medical ward at King Abdulaziz University Hospital, Jeddah, Saudi Arabia: A retrospective study

Bodoor S. Al-Dosari; Bayan M. Binafeef; Samar A. Alsolami

doi:10.15537/smj.2021.42.12.20210488

References

1.↵
1. Savarino V,
2. Marabotto E,
3. Zentilin P,
4. Furnari M,
5. Bodini G,
6. De Maria C, et al.
Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharmacol 2018; 11: 1123–1134.
OpenUrl PubMed
2.↵
1. Fossmark R,
2. Martinsen TC,
3. Waldum HL.
Adverse effects of proton pump inhibitors-evidence and plausibility. Int J Mol Sci 2019; 20: 5203.
OpenUrl
3.↵
1. Liu Y,
2. Zhu X,
3. Li R,
4. Zhang J,
5. Zhang F.
Proton pump inhibitor utilisation and potentially inappropriate prescribing analysis: insights from a single-centred retrospective study. BMJ Open 2020; 10: e040473.
OpenUrl Abstract/FREE Full Text
4.↵
1. Katz MH.
Failing the acid test: Benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med 2010; 170: 747–748.
OpenUrl CrossRef PubMed
5.↵
1. Hálfdánarson ÓÖ,
2. Pottegård A,
3. Björnsson ES,
4. Lund SH,
5. Ogmundsdottir MH,
6. Steingrímsson E, et al.
Proton-pump inhibitors among adults: a nationwide drug-utilization study. Therap Adv Gastroenterol 2018; 11: 1756284818777943.
OpenUrl
6.↵
1. Savarino V,
2. Marabotto E,
3. Zentilin P,
4. Furnari M,
5. Bodini G,
6. De Maria C, et al.
The appropriate use of proton-pump inhibitors. Minerva Medica 2018; 109: 386–399.
OpenUrl
7.↵
1. O’Mahony L,
2. Yelverton E.
Prescribing of proton pump inhibitors in an Irish general practice. Ir Med J 2019; 112: 932.
OpenUrl
8.↵
1. Madi L,
2. Ahmed Elhada AH,
3. Alrawashdeh H
, Ahmed A Prescribing pattern of proton pump inhibitors in Qatar rehabilitation institute: A retrospective study. J Res Pharm Pract 2019; 8: 101–104.
OpenUrl
9.
1. Jarbøl DE,
2. Lykkegaard J,
3. Hansen JM,
4. Munck A,
5. Haastrup PF.
Prescribing of proton-pump inhibitors: Auditing the management and reasons for prescribing in Danish general practice. Fam Pract 2019; 36: 758–764.
OpenUrl PubMed
10.↵
1. Kazberuk M,
2. Brzósko S,
3. Hryszko T,
4. Naumnik B.
Overuse of proton pump inhibitors and its consequences. Postepy Hig Med Dosw (Online) 2016; 70: 1112–1116.
OpenUrl
11.
1. Gamelas V,
2. Salvado V,
3. Dias L.
Prescription Pattern of Proton Pump Inhibitors at Hospital Admission and Discharge. GE Port J Gastroenterol 2019; 26: 114–120.
OpenUrl PubMed
12.↵
1. Ali MD,
2. Ahmad A.
A retrospective study on prescribing pattern and cost analysis of proton-pump inhibitors used among adults of Saudi Arabia. J Pharm Health Serv Res 2020; 11: 343–347.
OpenUrl
13.↵
1. Alzahrani MA,
2. Al Ghamdi BA,
3. Al ahmari HS,
4. Alqahtani EA,
5. Saleh AG,
6. Ahmed MEK
. The Prescribing Pattern of Proton Pump Inhibitors by Non-gastroenterologists in a Tertiary Teaching Hospital in the Kingdom of Saudi Arabia. JAASP 2016; 5: 341–345.
OpenUrl
14.↵
1. Alhossan A,
2. Alrabiah Z,
3. Alghadeer S,
4. Bablghaith S,
5. Wajid S,
6. Al-Arifi M.
Attitude and knowledge of Saudi community pharmacists towards use of proton pump inhibitors. Saudi Pharm J 2019; 27: 225–228.
OpenUrl
15.↵
1. Al-Worafi YM
, ed. Drug safety in Saudi Arabia. In: Drug Safety in Developing Countries. Elsevier; 2020. pp. 407–417.
16.↵
King Abdulaziz University Hospital. About Hospital. [Updated 2021; Accessed 2021 June 4]. Available from:https://hospital.kau.edu.sa/Content-599-EN-38308
17.↵
Wolters Kluwer. UpToDate. Evidence-based Clinical Decision Support. [Updated 2021; Accessed 2021 June 4]. Available from: https://www.wolterskluwer.com/en/solutions/uptodate
18.
International Business Machines Corporation (IBM). Micromedex solutions. Watson Health. [Updated 2021; Accessed 2021 June 4]. Available from URL: https://www.ibm.com/watson-health/about/micromedex
19.↵
National Institute for Health and Care Excellence. Guidelines on PPI. [Updated 2021; Accessed 2021 June 4]. Available from: https://www.evidence.nhs.uk/search?q=guidelines+on+ppi
20.↵
1. Mathew B,
2. Mathew J,
3. Kiran Y,
4. Geethu C,
5. Elsy Varghese S,
6. Ivan T, et al.
Study And Assessment Of Appropriateness In The Usage of Proton Pump Inhibitors In A Tertiary Care Teaching Hospital In South India. Indo Am J pharm 2015; 5: 2849–2856.
OpenUrl
21.↵
1. Thorsen K,
2. Søreide JA,
3. Kvaløy JT,
4. Glomsaker T,
5. Søreide K.
Epidemiology of perforated peptic ulcer: age-and gender-adjusted analysis of incidence and mortality. World J Gastroenterol 2013; 19: 347–354.
OpenUrl
22.↵
1. Hoover JG,
2. Schumaker AL,
3. Franklin KJ.
Use of intravenous proton-pump inhibitors in a teaching hospital practice. Dig Dis Sci 2009; 54: 1947–1952.
OpenUrl PubMed
23.↵
1. Barkun A,
2. Bardou M,
3. Marshall JK.
Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003; 139: 843–857.
OpenUrl CrossRef PubMed Web of Science
24.
1. Daneshmend TK,
2. Hawkey CJ,
3. Langman MJS,
4. Logan RF,
5. Long RG,
6. Walt RP.
Omeprazole versus placebo for acute upper gastrointestinal bleeding: Randomized double blind controlled trial. BMJ 1992; 304: 143–147.
OpenUrl Abstract/FREE Full Text
25.↵
1. Lin HJ,
2. Lo WC,
3. Lee FY,
4. Perng CL,
5. Tseng GY.
A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. Arch Intern Med 1998; 158: 54–58.
OpenUrl CrossRef PubMed Web of Science
26.↵
1. Akram F,
2. Huang Y,
3. Lim V,
4. Huggan PJ,
5. Merchant RA.
Proton pump inhibitors: Are we still prescribing them without valid indications? Australas Med J 2014; 7: 465–470.
OpenUrl PubMed
27.↵
1. Abraham NS.
Proton pump inhibitors: Potential adverse effects. Curr Opin Gastroenterol 2012; 28: 615–620.
OpenUrl CrossRef PubMed
28.
1. Theurl I,
2. Finkenstedt A,
3. Schroll A,
4. Nairz M,
5. Sonnweber T,
6. Bellmann-Weiler R, et al.
Growth differentiation factor 15 in anaemia of chronic disease, iron deficiency anaemia and mixed type anaemia. Br J Haematol 2010; 148: 449–455.
OpenUrl CrossRef PubMed Web of Science
29.↵
1. McCarthy D.
Iron deficiency anaemia due to proton pump inhibitors: clinical impact revealed. J Intern Med 2019; 285: 245–247.
OpenUrl
30.↵
1. Asdaq SMB,
2. ALbasha M,
3. Almutairi A,
4. Alyabisi R,
5. Almuhaisni A,
6. Faqihi R, et al.
Use of proton pump inhibitors: An exploration of awareness, attitude and behavior of health care professionals of Riyadh, Saudi Arabia. Saudi Pharm J 2021; 29: 713–718.
OpenUrl
31.↵
1. Mathioudakis A,
2. Rousalova I,
3. Gagnat AA,
4. Saad N,
5. Hardavella G.
How to keep good clinical records. Breathe (Sheff) 2016; 12: 369–373.
OpenUrl

In this issue

Download PDF

Email Article

Citation Tools

Bookmark this article

Cited By...

No citing articles found.

Google Scholar

More in this TOC Section

Show more Original Article

Keywords

[1] 1.↵
Savarino V,
Marabotto E,
Zentilin P,
Furnari M,
Bodini G,
De Maria C, et al.
Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharmacol 2018; 11: 1123–1134.
OpenUrl PubMed

[2] Savarino V,

[3] Marabotto E,

[4] Zentilin P,

[5] Furnari M,

[6] Bodini G,

[7] De Maria C, et al.

[8] 2.↵
Fossmark R,
Martinsen TC,
Waldum HL.
Adverse effects of proton pump inhibitors-evidence and plausibility. Int J Mol Sci 2019; 20: 5203.
OpenUrl

[9] Fossmark R,

[10] Martinsen TC,

[11] Waldum HL.

[12] 3.↵
Liu Y,
Zhu X,
Li R,
Zhang J,
Zhang F.
Proton pump inhibitor utilisation and potentially inappropriate prescribing analysis: insights from a single-centred retrospective study. BMJ Open 2020; 10: e040473.
OpenUrl Abstract/FREE Full Text

[13] Liu Y,

[14] Zhu X,

[15] Li R,

[16] Zhang J,

[17] Zhang F.

[18] 4.↵
Katz MH.
Failing the acid test: Benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med 2010; 170: 747–748.
OpenUrl CrossRef PubMed

[19] Katz MH.

[20] 5.↵
Hálfdánarson ÓÖ,
Pottegård A,
Björnsson ES,
Lund SH,
Ogmundsdottir MH,
Steingrímsson E, et al.
Proton-pump inhibitors among adults: a nationwide drug-utilization study. Therap Adv Gastroenterol 2018; 11: 1756284818777943.
OpenUrl

[21] Hálfdánarson ÓÖ,

[22] Pottegård A,

[23] Björnsson ES,

[24] Lund SH,

[25] Ogmundsdottir MH,

[26] Steingrímsson E, et al.

[27] 6.↵
Savarino V,
Marabotto E,
Zentilin P,
Furnari M,
Bodini G,
De Maria C, et al.
The appropriate use of proton-pump inhibitors. Minerva Medica 2018; 109: 386–399.
OpenUrl

[28] Savarino V,

[29] Marabotto E,

[30] Zentilin P,

[31] Furnari M,

[32] Bodini G,

[33] De Maria C, et al.

[34] 7.↵
O’Mahony L,
Yelverton E.
Prescribing of proton pump inhibitors in an Irish general practice. Ir Med J 2019; 112: 932.
OpenUrl

[35] O’Mahony L,

[36] Yelverton E.

[37] 8.↵
Madi L,
Ahmed Elhada AH,
Alrawashdeh H
, Ahmed A Prescribing pattern of proton pump inhibitors in Qatar rehabilitation institute: A retrospective study. J Res Pharm Pract 2019; 8: 101–104.
OpenUrl

[38] Madi L,

[39] Ahmed Elhada AH,

[40] Alrawashdeh H

[41] 9.
Jarbøl DE,
Lykkegaard J,
Hansen JM,
Munck A,
Haastrup PF.
Prescribing of proton-pump inhibitors: Auditing the management and reasons for prescribing in Danish general practice. Fam Pract 2019; 36: 758–764.
OpenUrl PubMed

[42] Jarbøl DE,

[43] Lykkegaard J,

[44] Hansen JM,

[45] Munck A,

[46] Haastrup PF.

[47] 10.↵
Kazberuk M,
Brzósko S,
Hryszko T,
Naumnik B.
Overuse of proton pump inhibitors and its consequences. Postepy Hig Med Dosw (Online) 2016; 70: 1112–1116.
OpenUrl

[48] Kazberuk M,

[49] Brzósko S,

[50] Hryszko T,

[51] Naumnik B.

[52] 11.
Gamelas V,
Salvado V,
Dias L.
Prescription Pattern of Proton Pump Inhibitors at Hospital Admission and Discharge. GE Port J Gastroenterol 2019; 26: 114–120.
OpenUrl PubMed

[53] Gamelas V,

[54] Salvado V,

[55] Dias L.

[56] 12.↵
Ali MD,
Ahmad A.
A retrospective study on prescribing pattern and cost analysis of proton-pump inhibitors used among adults of Saudi Arabia. J Pharm Health Serv Res 2020; 11: 343–347.
OpenUrl

[57] Ali MD,

[58] Ahmad A.

[59] 13.↵
Alzahrani MA,
Al Ghamdi BA,
Al ahmari HS,
Alqahtani EA,
Saleh AG,
Ahmed MEK
. The Prescribing Pattern of Proton Pump Inhibitors by Non-gastroenterologists in a Tertiary Teaching Hospital in the Kingdom of Saudi Arabia. JAASP 2016; 5: 341–345.
OpenUrl

[60] Alzahrani MA,

[61] Al Ghamdi BA,

[62] Al ahmari HS,

[63] Alqahtani EA,

[64] Saleh AG,

[65] Ahmed MEK

[66] 14.↵
Alhossan A,
Alrabiah Z,
Alghadeer S,
Bablghaith S,
Wajid S,
Al-Arifi M.
Attitude and knowledge of Saudi community pharmacists towards use of proton pump inhibitors. Saudi Pharm J 2019; 27: 225–228.
OpenUrl

[67] Alhossan A,

[68] Alrabiah Z,

[69] Alghadeer S,

[70] Bablghaith S,

[71] Wajid S,

[72] Al-Arifi M.

[73] 15.↵
Al-Worafi YM
, ed. Drug safety in Saudi Arabia. In: Drug Safety in Developing Countries. Elsevier; 2020. pp. 407–417.

[74] Al-Worafi YM

[75] 16.↵
King Abdulaziz University Hospital. About Hospital. [Updated 2021; Accessed 2021 June 4]. Available from:https://hospital.kau.edu.sa/Content-599-EN-38308

[76] 17.↵
Wolters Kluwer. UpToDate. Evidence-based Clinical Decision Support. [Updated 2021; Accessed 2021 June 4]. Available from: https://www.wolterskluwer.com/en/solutions/uptodate

[77] 18.
International Business Machines Corporation (IBM). Micromedex solutions. Watson Health. [Updated 2021; Accessed 2021 June 4]. Available from URL: https://www.ibm.com/watson-health/about/micromedex

[78] 19.↵
National Institute for Health and Care Excellence. Guidelines on PPI. [Updated 2021; Accessed 2021 June 4]. Available from: https://www.evidence.nhs.uk/search?q=guidelines+on+ppi

[79] 20.↵
Mathew B,
Mathew J,
Kiran Y,
Geethu C,
Elsy Varghese S,
Ivan T, et al.
Study And Assessment Of Appropriateness In The Usage of Proton Pump Inhibitors In A Tertiary Care Teaching Hospital In South India. Indo Am J pharm 2015; 5: 2849–2856.
OpenUrl

[80] Mathew B,

[81] Mathew J,

[82] Kiran Y,

[83] Geethu C,

[84] Elsy Varghese S,

[85] Ivan T, et al.

[86] 21.↵
Thorsen K,
Søreide JA,
Kvaløy JT,
Glomsaker T,
Søreide K.
Epidemiology of perforated peptic ulcer: age-and gender-adjusted analysis of incidence and mortality. World J Gastroenterol 2013; 19: 347–354.
OpenUrl

[87] Thorsen K,

[88] Søreide JA,

[89] Kvaløy JT,

[90] Glomsaker T,

[91] Søreide K.

[92] 22.↵
Hoover JG,
Schumaker AL,
Franklin KJ.
Use of intravenous proton-pump inhibitors in a teaching hospital practice. Dig Dis Sci 2009; 54: 1947–1952.
OpenUrl PubMed

[93] Hoover JG,

[94] Schumaker AL,

[95] Franklin KJ.

[96] 23.↵
Barkun A,
Bardou M,
Marshall JK.
Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003; 139: 843–857.
OpenUrl CrossRef PubMed Web of Science

[97] Barkun A,

[98] Bardou M,

[99] Marshall JK.

[100] 24.
Daneshmend TK,
Hawkey CJ,
Langman MJS,
Logan RF,
Long RG,
Walt RP.
Omeprazole versus placebo for acute upper gastrointestinal bleeding: Randomized double blind controlled trial. BMJ 1992; 304: 143–147.
OpenUrl Abstract/FREE Full Text

[101] Daneshmend TK,

[102] Hawkey CJ,

[103] Langman MJS,

[104] Logan RF,

[105] Long RG,

[106] Walt RP.

[107] 25.↵
Lin HJ,
Lo WC,
Lee FY,
Perng CL,
Tseng GY.
A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. Arch Intern Med 1998; 158: 54–58.
OpenUrl CrossRef PubMed Web of Science

[108] Lin HJ,

[109] Lo WC,

[110] Lee FY,

[111] Perng CL,

[112] Tseng GY.

[113] 26.↵
Akram F,
Huang Y,
Lim V,
Huggan PJ,
Merchant RA.
Proton pump inhibitors: Are we still prescribing them without valid indications? Australas Med J 2014; 7: 465–470.
OpenUrl PubMed

[114] Akram F,

[115] Huang Y,

[116] Lim V,

[117] Huggan PJ,

[118] Merchant RA.

[119] 27.↵
Abraham NS.
Proton pump inhibitors: Potential adverse effects. Curr Opin Gastroenterol 2012; 28: 615–620.
OpenUrl CrossRef PubMed

[120] Abraham NS.

[121] 28.
Theurl I,
Finkenstedt A,
Schroll A,
Nairz M,
Sonnweber T,
Bellmann-Weiler R, et al.
Growth differentiation factor 15 in anaemia of chronic disease, iron deficiency anaemia and mixed type anaemia. Br J Haematol 2010; 148: 449–455.
OpenUrl CrossRef PubMed Web of Science

[122] Theurl I,

[123] Finkenstedt A,

[124] Schroll A,

[125] Nairz M,

[126] Sonnweber T,

[127] Bellmann-Weiler R, et al.

[128] 29.↵
McCarthy D.
Iron deficiency anaemia due to proton pump inhibitors: clinical impact revealed. J Intern Med 2019; 285: 245–247.
OpenUrl

[129] McCarthy D.

[130] 30.↵
Asdaq SMB,
ALbasha M,
Almutairi A,
Alyabisi R,
Almuhaisni A,
Faqihi R, et al.
Use of proton pump inhibitors: An exploration of awareness, attitude and behavior of health care professionals of Riyadh, Saudi Arabia. Saudi Pharm J 2021; 29: 713–718.
OpenUrl

[131] Asdaq SMB,

[132] ALbasha M,

[133] Almutairi A,

[134] Alyabisi R,

[135] Almuhaisni A,

[136] Faqihi R, et al.

[137] 31.↵
Mathioudakis A,
Rousalova I,
Gagnat AA,
Saad N,
Hardavella G.
How to keep good clinical records. Breathe (Sheff) 2016; 12: 369–373.
OpenUrl

[138] Mathioudakis A,

[139] Rousalova I,

[140] Gagnat AA,

[141] Saad N,

[142] Hardavella G.

Main menu

User menu

Search

Prescribing pattern of proton pump inhibitors among patients admitted to medical ward at King Abdulaziz University Hospital, Jeddah, Saudi Arabia

A retrospective study

References

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords

CONTENT

JOURNAL

AUTHORS

Main menu

User menu

Search

Prescribing pattern of proton pump inhibitors among patients admitted to medical ward at King Abdulaziz University Hospital, Jeddah, Saudi Arabia

A retrospective study

References

In this issue

Citation Manager Formats

Jump to section

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords

CONTENT

JOURNAL

AUTHORS